2026 年 1 月 27 日，狄耐克与中国科学技术大学先进技术研究院（简称"中国科大先研院"）携手共建 的"脑机接口与大健康联合实验室"在中国科大先研院未来中心正式揭牌。据此，双方将重点围绕脑电信 号处理与分析展开合作，致力于研发更精准、更智能的算法模型，并推动其在具体场景的技术攻关与产 品转化，为"健康中国"建设注入全新科技动能。中国科学技术大学先进技术研究院副院长陈勋教授、厦 门狄耐克智能科技股份有限公司董事长缪国栋先生等出席揭牌仪式，共同见证双方在脑机接口技术转化 与大健康产业应用领域深化战略合作的重要时刻。(狄耐克) ...

公司通过产业投资基金间接投资的参股公司于2025年12月完成IPO发行上市，截至2025年12月31日相应 产生较高的公允价值变动收益，公司预计2025年度公允价值变动损益累计超4,000万元。该等收益计入 非经常性损益，对公司2025年度整体业绩产生一定的影响。 格隆汇1月28日丨狄耐克(300884.SZ)公布，预计2025年归属于上市公司股东的净利润1,000万元～1,500 万元，同比扭亏为盈，扣除非经常性损益后的净利润-4,400万元～-3,500万元。 ...

证券日报网讯1月28日，狄耐克（300884）在互动平台回答投资者提问时表示，截至2026年1月20日，公 司股东人数为27686户。 ...

南财智讯1月28日电，狄耐克发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为1000 万元—1500万元，预计同比扭亏；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润 为-4400万元—-3500万元。1、公司通过产业投资基金间接投资的参股公司于2025年12月完成IPO发行上 市，截至2025年12月31日相应产生较高的公允价值变动收益，公司预计2025年度公允价值变动损益累计 超4000万元。该等收益计入非经常性损益，对公司2025年度整体业绩产生一定的影响。2、公司2025年 度扣除非经常性损益后的净利润预计亏损3500万元至4400万元，较上年同期变动幅度为5.81% 至-18.40%。一方面，公司下游房地产市场需求仍面临缩减或延迟，公司整体营业收入下降；同时叠加 市场竞争加剧及原材料价格上涨，导致公司综合毛利率下滑，对公司业绩产生较大影响。另一方面，公 司持续加强费用管控，销售费用和管理费用等同比有所下降，导致2025年度公司扣除非经常性损益后的 净利润的变动幅度较上年同期有所收窄。 ...

Financial Performance Expectations - The company expects a net profit of between 10 million and 15 million CNY for the fiscal year 2025, marking a turnaround from a loss of 12.89 million CNY in the same period last year [5]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 35 million to 44 million CNY, which represents a change of -5.81% to -18.40% compared to the previous year [8]. - The company anticipates a significant fair value change gain exceeding 40 million CNY due to the IPO of an investee company, which will impact the overall performance for 2025 [7]. Revenue and Cost Management - The overall operating revenue is expected to decline due to reduced demand in the downstream real estate market and increased competition, alongside rising raw material costs affecting the gross profit margin [9]. - The company has implemented stricter cost control measures, resulting in a decrease in sales and management expenses compared to the previous year, which has helped narrow the loss in net profit after non-recurring items [9]. Compliance and Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with final figures to be confirmed in the annual report [6]. - The company will continue to comply with legal regulations regarding timely information disclosure to mitigate investment risks for stakeholders [10].

Core Viewpoint - The number of shareholders in 294 ChiNext stocks has decreased, with 160 stocks showing a decline compared to the previous period, and 13 stocks experiencing a drop of over 10% [1] Group 1: Shareholder Changes - Among the 294 ChiNext stocks, 160 reported a decrease in shareholder numbers, while 107 saw an increase [1] - The stock with the largest decline in shareholder numbers is Meihai Medical, which decreased by 30.08% to 29,576 shareholders, with a cumulative drop of 9.35% in stock price [1] - Jiuzhiyang reported a 24.15% decrease in shareholders, totaling 29,872, with a cumulative stock price drop of 12.94% [1] - Dineke's shareholder count fell by 18.13% to 27,686, with a stock price decline of 5.53% [1] Group 2: Continuous Concentration of Shareholders - A total of 21 ChiNext stocks have shown a continuous concentration of shareholders, with some experiencing a decline for more than three consecutive periods, and one stock has seen a decrease for seven consecutive periods [1] Group 3: Performance of Concentrated Stocks - The average increase for concentrated stocks since January 11 is 3.94%, with notable performers including Jiangtian Chemical, Ruixin Technology, and Green Island Wind, which increased by 39.33%, 31.32%, and 26.56% respectively [2] - In terms of industry concentration, the mechanical equipment, computer, and electronics sectors have the highest number of concentrated stocks, with 31, 17, and 16 stocks respectively [2] Group 4: Shareholder Count Declines - Hongming Co. has seen its shareholder count decrease by 22.01% to 3,905, marking a continuous decline for seven periods [2] - Anuoqi's shareholder count has dropped by 12.79% to 43,995, also reflecting a seven-period decline [2] - ST Qingyan's shareholder count decreased by 15.20% to 3,091, with a six-period decline [2] Group 5: Earnings Forecasts - Among the concentrated stocks, 18 have released earnings forecasts for the full year of 2025, with five expecting profit increases and one expecting a profit [3] - Huachen Equipment is projected to have the highest net profit growth at 217.84%, followed by Boteng Co. and Kaisheng New Materials with expected growth rates of 132.15% and 123.27% respectively [3]

Group 1 - The number of shareholders for the company as of January 20 is 27,686, a decrease of 6,131 from the previous period, representing a month-on-month decline of 18.13% [2] - The closing price of the company's stock is 15.75 yuan, with a slight increase of 0.32%, but the stock has cumulatively decreased by 7.41% since the concentration of shares began [2] - The company's third-quarter report indicates a total operating revenue of 461 million yuan for the first three quarters, a year-on-year decrease of 11.29%, and a net profit of -1.5979 million yuan, a year-on-year decline of 109.10%, with basic earnings per share at -0.0063 yuan [2]

Core Insights - The article discusses the transformation of China's healthcare system through the implementation of the open-source HarmonyOS, which is enhancing the efficiency and interconnectivity of hospital operations [1][2][3]. Group 1: Technological Advancements - The Chongqing Liangjiang New Area People's Hospital has implemented a smart system based on HarmonyOS, allowing real-time monitoring of patient status and significantly improving response times to incidents [1][3]. - The system integrates various devices, creating a seamless data flow across the hospital, which enhances patient autonomy and reduces the workload on nursing staff [2][3]. - The deployment of over 3,000 terminal devices has reduced incident response times from minutes to seconds and increased the satisfaction rate of personalized patient needs by approximately 80% [3]. Group 2: Systemic Challenges and Solutions - Traditional healthcare models face inefficiencies due to fragmented information flow and reliance on manual processes, leading to increased costs and wasted resources [2]. - The adoption of HarmonyOS is seen as a strategic choice that allows for customized development tailored to specific medical needs, overcoming limitations of traditional closed systems [3][5]. Group 3: Broader Implications for Healthcare - The transformation is not limited to new facilities; existing hospitals are also undergoing upgrades using HarmonyOS, which is facilitating a comprehensive reconfiguration of healthcare services [4][5]. - The integration of AI and HarmonyOS is expected to create a new ecosystem in healthcare, enhancing data security and system autonomy, which is crucial for the future of the industry [5][6]. Group 4: Industry Engagement - Several listed companies are actively investing in HarmonyOS-based healthcare solutions, indicating a growing interest in the intersection of AI and healthcare [6][7]. - Companies like Xiamen Dinake and Jiangsu Runkai Hong Digital Technology are developing innovative solutions that leverage HarmonyOS for integrated healthcare services, showcasing the potential for industry-wide transformation [6][7].

Group 1 - The company Dineike (300884) reported that as of January 9, 2026, the number of shareholders is 33,817 [1]

Group 1 - The core viewpoint of the news is that Dineike's stock has experienced fluctuations, with a recent decline of 2.00% and a current price of 17.15 CNY per share, while the company has seen a year-to-date increase of 15.88% [1] - Dineike's main business involves the research, design, production, and sales of smart community security devices, with revenue composition being 51.99% from intercom products, 22.44% from smart home products, 13.13% from smart ward and outpatient products, and 12.44% from other sources [2] - As of December 31, the number of Dineike's shareholders is 21,000, a decrease of 4.37% from the previous period, with an average of 9,129 circulating shares per person, an increase of 4.57% [2] Group 2 - In the first nine months of 2025, Dineike achieved operating revenue of 461 million CNY, a year-on-year decrease of 11.29%, and a net profit attributable to the parent company of -1.60 million CNY, a year-on-year decrease of 109.10% [2] - Dineike has distributed a total of 197 million CNY in dividends since its A-share listing, with 137 million CNY distributed in the last three years [3]